Comparative Pharmacology
Head-to-head clinical analysis: ADHANSIA XR versus DEXTROSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADHANSIA XR versus DEXTROSTAT.
ADHANSIA XR vs DEXTROSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adhansia XR is a central nervous system (CNS) stimulant. The mechanism of action in attention deficit hyperactivity disorder (ADHD) is not fully known, but it is thought to involve blockade of norepinephrine and dopamine reuptake into presynaptic neurons, increasing their levels in the synaptic cleft. This enhances attention and reduces impulsivity.
Dextroamphetamine is a central nervous system stimulant that promotes release of dopamine and norepinephrine from presynaptic neurons, and inhibits their reuptake, thereby increasing synaptic concentrations of these neurotransmitters.
Methylphenidate hydrochloride extended-release: Oral, 18-72 mg once daily in the morning.
5-60 mg orally per day in divided doses, typically 5-10 mg 2-3 times daily, maximum 60 mg/day.
None Documented
None Documented
Mean terminal elimination half-life is 7.5 hours (range 5-10 hours) following oral administration, allowing twice-daily dosing.
Terminal elimination half-life is approximately 10-13 hours in adults, 6-8 hours in children. Extended duration allows once-daily dosing in some patients.
Primarily renal (78% as unchanged drug), with 10% biliary/fecal elimination.
Primarily renal (approximately 90% as unchanged drug and metabolites); minor biliary/fecal elimination (<10%).
Category C
Category C
CNS Stimulant
CNS Stimulant